Powerful Science
Meaningful Medicines
Changing Lives

With its proprietary glycoPEGylated technology, BIO89-100 has the potential to provide robust and durable biologic effects, a favorable tolerability profile, and a long dosing interval for patients with NASH and SHTG.

Fibroblast growth factor 21 (FGF21), an endogenous metabolic hormone with broad-based effects, has the potential to become a mainstay of therapy for NASH and SHTG as it directly addresses the multiple facets of the diseases, as well as the underlying metabolic dysregulation often seen in these patients resulting in multiple related disorders.

We have reported positive data from our proof-of-concept phase 1b/2a clinical trial evaluating BIO89-100 in NASH and we are currently studying BIO89-100 for the treatment of SHTG.